#
Uceris Tablets
  • Professionals
  • FDA PI

Uceris Tablets

Generic name:budesonide
Dosage form: tablet, extended release
Drug class:Glucocorticoids

Medically reviewed by Drugs.com. Last updated on Mar 22, 2022.

Indications and Usage for Uceris Tablets

UCERIS® extended-release tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.

Uceris Tablets Dosage and Administration

Mild to Moderate Ulcerative Colitis

The recommended dosage for the induction of remission in adult patients with active, mild to moderate ulcerative colitis is 9 mg taken orally once daily in the morning with or without food for up to 8 weeks. UCERIS should be swallowed whole and not chewed, crushed or broken.

CYP3A4 Inhibitors

If concomitant administration with ketoconazole, or any other CYP3A4 inhibitor, is indicated, patients should be closely monitored for increased signs and/or symptoms of hypercorticism. Avoid grapefruit juice, which is known to inhibit CYP3A4, when taking UCERIS. In these cases, discontinuation of UCERIS or the CYP3A4 inhibitor should be considered [see Drug Interactions (7) and Clinical Pharmacology (12.3)].

Dosage Forms and Strengths

White, round, biconvex extended-release tablets debossed with “MX9”. Each extended-release tablet contains 9 mg budesonide.

Contraindications

UCERIS is contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of UCERIS. Anaphylactic reactions have occurred with o...